Abstract:Introduction: The factors responsible for NSCLC development in never-smokers remain unclear, thus hindering prevention efforts. Our group is one of the first in the U.S. to build a registry of never-smokers with NSCLC to facilitate research to address this global problem. Given the high prevalence of women among cases, we are investigating the contribution of estrogen metabolism to this disease. CYP1B1 converts parent estrogens to the putative carcinogen 4-hydroxyestrogen (4-OHE), a process further accelerated by tobacco smoke exposure. In contrast, CYP1A1 generates 2-hydroxyestrogen (2-OHE), which may be converted to anti-proliferative derivatives. We determined previously that women with EGFR-mutant NSCLC enrolled in the registry have a 2-fold higher ratio of 4-OHEs to 2-OHEs, as compared to cancer-free controls. While EGFR-mutant NSCLCs are typically thought to be diagnosed in never-smokers, prior data indicate that a fraction of patients report some smoking history. The goal of this current study is to determine the smoking prevalence among women with EGFR-mutant NSCLC in our registry and explore the impact of smoking and hormonal history on estrogen metabolism. Methods: The Lung Cancer in Never-Smokers Risk Registry (LCNS-RR) is recruiting patients with NSCLC who are never-smokers (<100 cigarettes/lifetime) and/or have tumors with oncogenes characteristically present in never-smokers (e.g., EGFR, ALK). In addition to donating biospecimens (e.g., blood, urine), participants complete a survey on tobacco and environmental exposures, hormonal history, and other factors. Using UPLC-MS/MS, profiles of urinary estrogens (E1, E2, E3, 4-OHE1, 4-OHE2, 2-OHE1, 2-OHE2) were determined for 32 women with EGFR-mutant NSCLC in the LCNS-RR. The proportion of each estrogen species over total estrogen and the ratio of 4-OHEs to 2-OHEs were calculated. Medians were compared using the Wilcoxon rank-sum test. Results: Among women in this EGFR-mutant cohort, none were current smokers, 16 were former smokers, and 16 were never-smokers. Among the former smokers, median pack-years was 11.6. The ratio of 4-OHEs to 2-OHEs was comparable in former- vs. never-smokers (0.51 vs. 0.49, p-value = 0.956). Twenty-three women (71.8%) had a history of oral contraception use, and 5 (15.6%) reported early menarche (<12 years of age). However, neither of these factors correlated with 4-OHE production. Among 28 post-menopausal women, 7 (25%) reported estrogen use since menopause, an exposure that was not associated with 4-OHE levels. Conclusion: This preliminary analysis suggests that smoking history, use of hormones, or early menarche do not enhance the production of 4-OHEs in women with EGFR-mutant NSCLC. Recruitment to the LCNS-RR is ongoing and will facilitate future analyses in a larger cohort. (Supported by a Ride Hard Breathe Easy Innovation Award) Citation Format: Ahmad Raza, Joseph Treat, Daniel D. Krzizike, Lisa Vanderveer, Mitchell Cheung, Carolyn Zawislak, Lisa Etkins, Eric Ross, Douglas B. Flieder, Martin J. Edelman, Margie L. Clapper, J Nicholas Bodor. Tobacco smoke exposure, hormonal history, and estrogen metabolism in women with EGFR-mutant non-small cell lung cancer (NSCLC) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 765.

Abstract 1748: Dearth of smoking-induced mutations in oncogene-driven NSCLCs despite smoking exposure

Combined Effects of Cigarette Smoking, Gene Polymorphisms and Methylations of Tumor Suppressor Genes on Non Small Cell Lung Cancer: a Hospital-Based Case-Control Study in China

From tobacco smoking to mutational signature: the role of epigenetic changes in human cancers

Abstract 3934: Smoking's influence on divergent paths to lung cancer

Uncommon/rare oncogenic drivers in non‐small cell lung cancer: Consensus and contention

Prognostic factors for survival in a Chinese population presenting with advanced non-small cell lung cancer with an emphasis on smoking status: A regional, single-institution, retrospective analysis of 4552 patients

Abstract 5061: Improved survival and unique mutational signatures in small cell lung cancer arising in patients with limited tobacco use

Abstract 1166: APOBEC deaminases compete with tobacco smoking mutagenesis and affect age at onset of lung cancer

Abstract 5657: The intricate relationship between genomic damage and epidemiological lung cancer risk in ever-smokers

Abstract LB231: The mutagenic forces shaping the genomic landscape of lung cancer in never smokers

Frequency of Well-Identified Oncogenic Driver Mutations in Lung Adenocarcinoma of Smokers Varies with Histological Subtypes and Graduated Smoking Dose.

Abstract 5062: Evaluation of genetic mutations in non-small cell lung cancer patients

Cigarette Smoking, BPDE-DNA Adducts, and Aberrant Promoter Methylations of Tumor Suppressor Genes (TSGs) in NSCLC from Chinese Population

Analysis of Driver Mutations in Female Non-Smoker Asian Patients with Pulmonary Adenocarcinoma

Smoking Alters the Evolutionary Trajectory of Non-Small Cell Lung Cancer.

The mutagenic forces shaping the genomic landscape of lung cancer in never smokers

Smoking-Related Genomic Signatures In Non-Small Cell Lung Cancer

Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers

Abstract 765: Tobacco smoke exposure, hormonal history, and estrogen metabolism in women with EGFR-mutant non-small cell lung cancer (NSCLC)

Abstract 7581: Nicotine promotes the proliferation and metastasis of non-small cell lung cancer through c-Myc/EZH2 pathway

Abstract 1980: Cigarette smoke induced oxidative phosphorylation and mitochondrial biogenesis enhance response to immune therapy in NSCLC patients